Observational studyThe Lancet. Haematology2025

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study.

Hege Kristin Gravdahl Garelius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.